Andreou NP, Legaki E, Dovrolis N, et al. - Since several studies correlated elevated B-cell activating factor (BAFF) levels and its polymorphisms (SNPs) in patients with autoimmunity, researchers sought to assess BAFF expression in Crohn disease (CD) patients to investigate whether its expression predicts response to infliximab treatment and to explore the relationship of BAFF SNPs with CD susceptibility. Participants in the study were 112 CD patients and 164 healthy controls. In CD patients, serum BAFF concentration was elevated relative to controls before treatment. Compared to non-responders, responders to IFX treatment had increased serum BAFF levels at baseline. In responders, BAFF concentration reduced after IFX administration, while increased in non-responders. The rs1041569, TA and AA genotypes frequencies, and the minor allele A were increased significantly in CD patients, indicating an association of the SNP with CD susceptibility. The study indicates that BAFF could be a potential CD biomarker, while CD susceptibility was associated with SNP rs1041569.